KMDA
Price
$7.88
Change
+$0.14 (+1.81%)
Updated
Jul 3 closing price
Capitalization
306.49M
39 days until earnings call
RDY
Price
$15.08
Change
+$0.20 (+1.34%)
Updated
Jul 3 closing price
Capitalization
12.48B
18 days until earnings call
Interact to see
Advertisement

KMDA vs RDY

Header iconKMDA vs RDY Comparison
Open Charts KMDA vs RDYBanner chart's image
Kamada
Price$7.88
Change+$0.14 (+1.81%)
Volume$23.33K
Capitalization306.49M
Dr. Reddy's Laboratories
Price$15.08
Change+$0.20 (+1.34%)
Volume$583.44K
Capitalization12.48B
KMDA vs RDY Comparison Chart in %
Loading...
KMDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KMDA vs. RDY commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KMDA is a StrongBuy and RDY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (KMDA: $7.88 vs. RDY: $15.08)
Brand notoriety: KMDA and RDY are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: KMDA: 31% vs. RDY: 36%
Market capitalization -- KMDA: $306.49M vs. RDY: $12.48B
KMDA [@Pharmaceuticals: Other] is valued at $306.49M. RDY’s [@Pharmaceuticals: Other] market capitalization is $12.48B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KMDA’s FA Score shows that 1 FA rating(s) are green whileRDY’s FA Score has 1 green FA rating(s).

  • KMDA’s FA Score: 1 green, 4 red.
  • RDY’s FA Score: 1 green, 4 red.
According to our system of comparison, RDY is a better buy in the long-term than KMDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KMDA’s TA Score shows that 4 TA indicator(s) are bullish while RDY’s TA Score has 4 bullish TA indicator(s).

  • KMDA’s TA Score: 4 bullish, 4 bearish.
  • RDY’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, KMDA is a better buy in the short-term than RDY.

Price Growth

KMDA (@Pharmaceuticals: Other) experienced а -0.25% price change this week, while RDY (@Pharmaceuticals: Other) price change was -1.63% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.02%. For the same industry, the average monthly price growth was +2.94%, and the average quarterly price growth was +92.60%.

Reported Earning Dates

KMDA is expected to report earnings on Aug 13, 2025.

RDY is expected to report earnings on Jul 23, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+2.02% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RDY($12.5B) has a higher market cap than KMDA($306M). KMDA has higher P/E ratio than RDY: KMDA (37.43) vs RDY (19.68). KMDA YTD gains are higher at: 33.100 vs. RDY (-4.497). RDY has higher annual earnings (EBITDA): 84.9B vs. KMDA (22.4M). RDY has more cash in the bank: 72.4B vs. KMDA (55.6M). KMDA has less debt than RDY: KMDA (8.82M) vs RDY (19.9B). RDY has higher revenues than KMDA: RDY (271B) vs KMDA (143M).
KMDARDYKMDA / RDY
Capitalization306M12.5B2%
EBITDA22.4M84.9B0%
Gain YTD33.100-4.497-736%
P/E Ratio37.4319.68190%
Revenue143M271B0%
Total Cash55.6M72.4B0%
Total Debt8.82M19.9B0%
FUNDAMENTALS RATINGS
KMDA vs RDY: Fundamental Ratings
KMDA
RDY
OUTLOOK RATING
1..100
1377
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
81
Overvalued
PROFIT vs RISK RATING
1..100
9832
SMR RATING
1..100
8048
PRICE GROWTH RATING
1..100
4051
P/E GROWTH RATING
1..100
2857
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KMDA's Valuation (73) in the Biotechnology industry is in the same range as RDY (81) in the Pharmaceuticals Generic industry. This means that KMDA’s stock grew similarly to RDY’s over the last 12 months.

RDY's Profit vs Risk Rating (32) in the Pharmaceuticals Generic industry is significantly better than the same rating for KMDA (98) in the Biotechnology industry. This means that RDY’s stock grew significantly faster than KMDA’s over the last 12 months.

RDY's SMR Rating (48) in the Pharmaceuticals Generic industry is in the same range as KMDA (80) in the Biotechnology industry. This means that RDY’s stock grew similarly to KMDA’s over the last 12 months.

KMDA's Price Growth Rating (40) in the Biotechnology industry is in the same range as RDY (51) in the Pharmaceuticals Generic industry. This means that KMDA’s stock grew similarly to RDY’s over the last 12 months.

KMDA's P/E Growth Rating (28) in the Biotechnology industry is in the same range as RDY (57) in the Pharmaceuticals Generic industry. This means that KMDA’s stock grew similarly to RDY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KMDARDY
RSI
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
65%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
68%
Bullish Trend 3 days ago
59%
Momentum
ODDS (%)
Bullish Trend 3 days ago
73%
Bearish Trend 3 days ago
43%
MACD
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
53%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
68%
Bearish Trend 3 days ago
51%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
69%
Bullish Trend 3 days ago
46%
Advances
ODDS (%)
Bullish Trend 26 days ago
67%
Bullish Trend 24 days ago
51%
Declines
ODDS (%)
Bearish Trend 23 days ago
67%
Bearish Trend 4 days ago
51%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
65%
Bearish Trend 3 days ago
39%
Aroon
ODDS (%)
Bullish Trend 3 days ago
69%
Bullish Trend 3 days ago
42%
View a ticker or compare two or three
Interact to see
Advertisement
KMDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IXC40.15N/A
N/A
iShares Global Energy ETF
HLGE31.91N/A
N/A
Hartford Longevity Economy ETF
BFZ10.86-0.03
-0.28%
BLACKROCK CA Municipal
FIVY40.50-0.14
-0.34%
YieldMax Dorsey Wright Hybrid 5 Inc ETF
PGP8.30-0.06
-0.72%
PIMCO Global StockPLUS & Income Fund

KMDA and

Correlation & Price change

A.I.dvisor tells us that KMDA and OGI have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KMDA and OGI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KMDA
1D Price
Change %
KMDA100%
+1.81%
OGI - KMDA
30%
Poorly correlated
+3.62%
RDY - KMDA
28%
Poorly correlated
+1.34%
AMRX - KMDA
26%
Poorly correlated
+0.60%
ELAN - KMDA
24%
Poorly correlated
-0.54%
HROW - KMDA
24%
Poorly correlated
+3.86%
More

RDY and

Correlation & Price change

A.I.dvisor tells us that RDY and COLL have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RDY and COLL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RDY
1D Price
Change %
RDY100%
+1.34%
COLL - RDY
31%
Poorly correlated
-0.52%
KMDA - RDY
28%
Poorly correlated
+1.81%
AMPH - RDY
26%
Poorly correlated
-1.61%
OGI - RDY
26%
Poorly correlated
+3.62%
HROW - RDY
25%
Poorly correlated
+3.86%
More